Insulin resistance and chronic hepatitis C
- Authors: Tkachenko LI1, Maleev VV2
-
Affiliations:
- Ставропольский государственный медицинский университет Минздрава России
- Центральный НИИ эпидемиологии Роспотребнадзора
- Issue: Vol 88, No 11 (2016)
- Pages: 29-36
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32060
- DOI: https://doi.org/10.17116/terarkh2016881129-36
- ID: 32060
Cite item
Full Text
Abstract
Aim. To estimate the spread of insulin resistance (IR) in patients with chronic hepatitis C (CHC) and to define the role of IR in the development of hepatic steatosis (HS) and in the progression of liver fibrosis (LF), as well as the impact of IR on the results of antiviral therapy (AVT). Subjects and methods. A total of 211 patients with CHC were examined. A comparison group consisted of 75 patients with chronic hepatitis B (CHB). The patients were divided according to the presence and absence of IR and type 2 diabetes mellitus (DM). IR was analyzed in patients with CHC with a body mass index (BMI) of <25 kg/m2 and with the initial manifestations of LF. Results. In the patients with CHC, IR without DM was 1.7-fold more common and type 2 DM was 2.6 times more frequently seen than in those with CHB. The highest biochemical activity, subclinical inflammation (as evaluated from ferritin and C-reactive protein levels), and an advanced LF stage were noted in the presence of IR and type DM. IR and type 2 DM were associated with metabolic syndrome and its individual components and with no response to AVT. When the BMI was <25 kg/m2, HS, inadequate 25(OH)D provision, an advanced LF stage, and slowly progressive inflammation were related to IR. In the presence of the initial manifestations of fibrosis, IR was associated with obesity, HS, 25(OH)D deficiency, a rise in C-reactive protein greater than 3 mg/l, and no response to AVT. Conclusion. The presence of IR in CHC patients with a BMI of <25 kg/m2 and with the initial manifestations of LF and the association of IR with HS and an advanced LF stage necessitate an examination of all patients with CHC in an effort to identify IR and to perform active therapy of detected abnormalities.
About the authors
L I Tkachenko
Ставропольский государственный медицинский университет Минздрава РоссииСтаврополь, Россия
V V Maleev
Центральный НИИ эпидемиологии РоспотребнадзораМосква, Россия
References
- Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416-423. doi: 10.1053/j.gastro.2007.11.010
- Camm`a C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006;43:64-71. doi: 10.1002/hep.20983/pdf
- Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis. Minerva Gastroenterol Dietol. 2006;52(2):125-134. www.ncbi.nlm.nih.gov/pubmed/16557184
- White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831-844. doi: 10.1016/j.jhep.2008.08.006
- Bordelon P, Ghetu M, Langan R. Recognition and management of vitamin D deficiency. Am Fam Physician. 2009;80(8):841-846. www.aafp.org/afp/2009/1015/p841.html
- Bess Dawson-Hughes, Robert P, Heaney, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713-716.
- Mari A, Ahren B, Pacini G. Assessment of insulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab Care. 2005;8:529-533.
- Persico M, Masarone M, La Mura V, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. World J Gastroenterol. 2009;15(4):462-466. doi: 10.3748/wjg.15.462
- Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15(13):1537-1547. doi: 10.3748/wjg.15.1537
- Perlemuter G, Sabile A, LetteronP, Vona G, Topilco A´, Chre´Tien Y, Koike K, Pessayre D, Chapman J, Barba G, and Bre´ Chot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16:185-194. doi: 10.1096/fj.01-0396com
- Никитин И.Г., Богомолов П.О. Инсулинорезистентность и гепатит С: могут ли наши новые представления изменить подходы к лечению? Фарматека. 2007;2(137):15-19.
- Mirandola S, BowmanD, Hussain M, Alberti A. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP) Nutrition Metabol. 2010;7:13. doi: 10.1186/1743-7075-7-13
- Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology. 2003;125:1695-1704. doi: 10.1053/j.gastro.2003.08.032
- Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Shin SJ, Chang WY, Chuang WL, Yu ML. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102(6):1237-1243. doi: 10.1111/j.1572-0241.2007.01181.x
- Pfützner A, Schöndorf T, Hanefeld M, Forst T. High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone. J Diabetes Sci Technol. 2010;4(3):706-716.
- Popović-Dragonjić L, Jovanović M, Vrbić M, Konstantinović L, Kostić V, Dragonjić I. Нigh sensitivity С-reactive protein as prediction factor of disease progression in patients with chronic hepatitis С and mild liver Steatosis. Acta Medica Medianae. 2010;49(3):14-18.
- Mahajan A, Tabassum R, Chavali S, Prakash Dwivedi O, Bharadwaj M, Tandon N, Bharadwaj D. High-Sensitivity C-Reactive Protein Levels and Type 2Diabetes in Urban North Indians. Clin Endocrinol Metab. 2009;94:2123-2127. doi: 10.1210/jc.2008-2754
![](/img/style/loading.gif)